CellAegis Devices Inc. Announces Initiation of Clinical Testing of Remote Ischemic Conditioning (RIC) Using the autoRIC Device for Patients Undergoing Partial Nephrectomy
11/12/2012 10:26:46 AM
TORONTO--(BUSINESS WIRE)--CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval (ITA) from Health Canada which allows the initiation of clinical testing in Canada of the Company’s autoRIC™ Device for remote ischemic conditioning (RIC). In a pilot clinical trial sponsored by Michael Jewett, M.D., of the University Health Network - Princess Margaret Hospital in Toronto, RIC will be evaluated for its ability to reduce acute kidney injury induced by intraoperative renal ischemia during partial nephrectomy. This is the second clinical trial to incorporate CellAegis’ autoRIC Device. In August, the Company announced the initiation of an Aarhus University-sponsored clinical trial program in Europe utilizing the autoRIC Device for patients with evolving ST-elevation myocardial infarction (STEMI).
comments powered by